Phase 1 study of inotuzumab ozogamicin combined with R-GDP for the treatment of patients with relapsed/refractory CD22+ B-cell non-Hodgkin lymphoma
Randeep Sangha, Andrew Davies, Nam H Dang, Michinori Ogura, David A MacDonald, Revathi Ananthakrishnan, M Luisa Paccagnella, Erik Vandendries, Joseph Boni, Yeow Tee Goh, Randeep Sangha, Andrew Davies, Nam H Dang, Michinori Ogura, David A MacDonald, Revathi Ananthakrishnan, M Luisa Paccagnella, Erik Vandendries, Joseph Boni, Yeow Tee Goh
Abstract
Objective: To evaluate safety, tolerability, and preliminary activity of inotuzumab ozogamicin (InO) plus rituximab, gemcitabine, dexamethasone, and cisplatin (R-GDP) in patients with relapsed/refractory CD22+ B-cell non-Hodgkin lymphoma (NHL). Methods: Patients received InO plus R-GDP (21-day cycle; six-cycle maximum) using up-and-down dose-escalation schema for gemcitabine and cisplatin to define the highest dosage regimen(s) with acceptable toxicity (Part 1; n = 27). Part 2 (n = 10) confirmed safety and tolerability; Part 3 (n = 18) evaluated preliminary efficacy. Results: Among 55 patients enrolled, 42% were refractory at baseline (median 2 [range, 1-6] prior therapies); 38% had diffuse large B-cell lymphoma (DLBCL). The highest dosage regimen with acceptable toxicity was InO 0.8 mg/m2, rituximab 375 mg/m2, cisplatin 50 mg/m2, gemcitabine 500 mg/m2 (day 1 only) and dexamethasone 40 mg (days 1-4); this was confirmed in Part 2, in which three patients had dose-limiting toxicities (grade 4 thrombocytopenia [n = 2], febrile neutropenia [n = 2]). Most frequent treatment-related adverse events were thrombocytopenia (any grade, 85%; grade ≥3, 75%) and neutropenia (69%; 62%). Overall (objective) response rate (ORR) was 53% (11 complete, 18 partial responses); ORR was 71%, 33%, and 62% in patients with follicular lymphoma (n = 14), DLBCL (n = 21), and mantle cell lymphoma (n = 13), respectively. Conclusions: InO 0.8 mg/m2 plus R-GDP was associated with manageable toxicity, although gemcitabine and cisplatin doses were lower than in the standard R-GDP regimen due to hematologic toxicity. Evidence of antitumor activity was observed; however, these exploratory data should be interpreted with caution due to the small sample size and short follow-up duration (Clinicaltrials.gov number: NCT01055496).
Keywords: B-cell non-Hodgkin lymphoma; CD22+; Inotuzumab ozogamicin; antibody-conjugate; chemotherapy; rituximab.
Figures
References
- Leonard JP, Coleman M, Ketas JC, et al. . Epratuzumab, a humanized anti-CD22 antibody, in aggressive non-Hodgkin's lymphoma: phase I/II clinical trial results. Clin Cancer Res. 2004;10(16):5327-5334.
- Cesano A, Gayko U.. CD22 as a target of passive immunotherapy. Semin Oncol. 2003;30(2):253-257.
- Vaickus L, Ball ED, Foon KA.. Immune markers in hematologic malignancies. Crit Rev Oncol Hematol. 1991;11(4):267-297.
- Hinman LM, Hamann PR, Wallace R, et al. . Preparation and characterization of monoclonal antibody conjugates of the calicheamicins: a novel and potent family of antitumor antibiotics. Cancer Res. 1993;53(14):3336-3342.
- Hamann PR, Hinman LM, Hollander I, et al. . Gemtuzumab ozogamicin, a potent and selective anti-CD33 antibody–calicheamicin conjugate for treatment of acute myeloid leukemia. Bioconjug Chem. 2002;13(1):47-58.
- DiJoseph JF, Armellino DC, Boghaert ER, et al. . Antibody-targeted chemotherapy with CMC-544: a CD22-targeted immunoconjugate of calicheamicin for the treatment of B-lymphoid malignancies. Blood. 2004;103(5):1807-1814.
- Advani A, Coiffier B, Czuczman MS, et al. . Safety, pharmacokinetics, and preliminary clinical activity of inotuzumab ozogamicin, a novel immunoconjugate for the treatment of B-cell non-Hodgkin's lymphoma: results of a phase I study. J Clin Oncol. 2010;28(12):2085-2093.
- Ogura M, Tobinai K, Hatake K, et al. . Phase I study of inotuzumab ozogamicin (CMC-544) in Japanese patients with follicular lymphoma pretreated with rituximab-based therapy. Cancer Sci. 2010;101(8):1840-1845.
- Ogura M, Hatake K, Ando K, et al. . Phase I study of anti-CD22 immunoconjugate inotuzumab ozogamicin plus rituximab in relapsed/refractory B-cell non-Hodgkin lymphoma. Cancer Sci. 2012;103(5):933-938.
- Dang NH, Ogura M, Castaigne S, et al. . Randomized, phase 3 trial of inotuzumab ozogamicin plus rituximab (R-InO) versus chemotherapy for relapsed/refractory aggressive B-cell non-Hodgkin lymphoma (B-NHL). J Clin Oncol. 2014;32(15 Suppl):8529.
- Fayad L, Offner F, Smith MR, et al. . Safety and clinical activity of a combination therapy comprising two antibody-based targeting agents for the treatment of non-Hodgkin lymphoma: results of a phase I/II study evaluating the immunoconjugate inotuzumab ozogamicin with rituximab. J Clin Oncol. 2013;31(5):573-583.
- DiJoseph JF, Dougher MM, Evans DY, et al. . Preclinical anti-tumor activity of antibody-targeted chemotherapy with CMC-544 (inotuzumab ozogamicin), a CD22-specific immunoconjugate of calicheamicin, compared with non-targeted combination chemotherapy with CVP or CHOP. Cancer Chemother Pharmacol. 2011;67(4):741-749.
- Data on file. New York, NY: Pfizer Inc; 2014.
- Gandhi L, Bahleda R, Tolaney SM, et al. . Phase I study of neratinib in combination with temsirolimus in patients with human epidermal growth factor receptor 2-dependent and other solid tumors. J Clin Oncol. 2014;32(2):68-75.
- Ivanova A, Wang K.. A non-parametric approach to the design and analysis of two-dimensional dose-finding trials. Stat Med. 2004;23(12):1861-1870.
- Isakoff SJ, Wang D, Campone M, et al. . Bosutinib plus capecitabine for selected advanced solid tumours: results of a phase 1 dose-escalation study. Br J Cancer. 2014;111(11):2058-2066.
- Cheson BD, Pfistner B, Juweid ME, et al. . Revised response criteria for malignant lymphoma. J Clin Oncol. 2007;25(5):579-586.
- Halwani AS, Link BK.. Chemotherapy and antibody combinations for relapsed/refractory non-Hodgkin's lymphoma. Expert Rev Anticancer Ther. 2011;11(3):443-455.
- Griffin MM, Morley N.. Rituximab in the treatment of non-Hodgkin's lymphoma—a critical evaluation of randomized controlled trials. Expert Opin Biol Ther. 2013;13(5):803-811.
- Hagemeister F. Rituximab for the treatment of non-Hodgkin's lymphoma and chronic lymphocytic leukaemia. Drugs. 2010;70(3):261-272.
- Keating GM. Spotlight on rituximab in chronic lymphocytic leukemia, low-grade or follicular lymphoma, and diffuse large B-cell lymphoma. BioDrugs. 2011;25(1):55-61.
- Tarella C, Zanni M, Magni M, et al. . Rituximab improves the efficacy of high-dose chemotherapy with autograft for high-risk follicular and diffuse large B-cell lymphoma: a multicenter Gruppo Italiano Terapie Innnovative nei linfomi survey. J Clin Oncol. 2008;26(19):3166-3175.
- Crump M, Baetz T, Couban S, et al. . Gemcitabine, dexamethasone, and cisplatin in patients with recurrent or refractory aggressive histology B-cell non-Hodgkin lymphoma: a Phase II study by the National Cancer Institute of Canada Clinical Trials Group (NCIC-CTG). Cancer. 2004;101(8):1835-1842.
- Morschhauser F, Depil S, Jourdan E, et al. . Phase II study of gemcitabine-dexamethasone with or without cisplatin in relapsed or refractory mantle cell lymphoma. Ann Oncol. 2007;18(2):370-375.
- Griffiths R, Mikhael J, Gleeson M, et al. . Addition of rituximab to chemotherapy alone as first-line therapy improves overall survival in elderly patients with mantle cell lymphoma. Blood. 2011;118(18):4808-4816.
- Rummel MJ, Niederle N, Maschmeyer G, et al. . Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial. Lancet. 2013;381(9873):1203-1210.
Source: PubMed